Esperion Therapeutics’ (ESPR) “Market Outperform” Rating Reiterated at JMP Securities

JMP Securities restated their market outperform rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a report issued on Thursday morning,Benzinga reports. They currently have a $7.00 price objective on the biopharmaceutical company’s stock.

A number of other brokerages have also issued reports on ESPR. HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a research note on Thursday. The Goldman Sachs Group initiated coverage on Esperion Therapeutics in a research note on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 target price for the company. Needham & Company LLC reissued a “buy” rating and issued a $6.00 price objective on shares of Esperion Therapeutics in a report on Friday, December 13th. Cantor Fitzgerald initiated coverage on Esperion Therapeutics in a report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 target price for the company. Finally, StockNews.com downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $7.25.

Esperion Therapeutics Trading Up 1.0 %

Shares of ESPR opened at $2.10 on Thursday. Esperion Therapeutics has a 12 month low of $1.58 and a 12 month high of $3.94. The stock has a fifty day moving average price of $2.46 and a 200-day moving average price of $2.17. The firm has a market cap of $413.78 million, a PE ratio of -3.28 and a beta of 1.03.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.01). The business had revenue of $51.63 million during the quarter, compared to analyst estimates of $55.44 million. During the same period in the previous year, the company posted ($0.37) earnings per share. As a group, research analysts forecast that Esperion Therapeutics will post -0.28 EPS for the current year.

Institutional Trading of Esperion Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ESPR. China Universal Asset Management Co. Ltd. acquired a new position in Esperion Therapeutics in the fourth quarter valued at approximately $92,000. Foundations Investment Advisors LLC lifted its stake in shares of Esperion Therapeutics by 48.6% in the 4th quarter. Foundations Investment Advisors LLC now owns 30,172 shares of the biopharmaceutical company’s stock valued at $66,000 after purchasing an additional 9,872 shares during the period. SJS Investment Consulting Inc. acquired a new position in shares of Esperion Therapeutics in the 4th quarter valued at $55,000. SG Americas Securities LLC boosted its holdings in Esperion Therapeutics by 96.6% during the fourth quarter. SG Americas Securities LLC now owns 151,482 shares of the biopharmaceutical company’s stock worth $333,000 after buying an additional 74,433 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in Esperion Therapeutics by 1.0% during the third quarter. JPMorgan Chase & Co. now owns 2,069,117 shares of the biopharmaceutical company’s stock valued at $3,414,000 after buying an additional 19,588 shares during the period. 47.39% of the stock is owned by institutional investors and hedge funds.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.